naltrexone inhibits il-6 and TnFα Production in human immune cell subsets following stimulation with ligands for intracellular Toll-like receptors


Category: General

Date: Jul 2017

Author: Rachel Cant

Type: Article

The opioid antagonist naltrexone hydrochloride has been suggested to be a potential therapy at low dosage for multiple inflammatory conditions and cancers. Little is known about the immune-modulating effects of naltrexone, but an effect on the activity of toll-like receptor 4 (TLR4) has been reported.

{"email":"Email address invalid","url":"Website address invalid","required":"Required field missing"}

Not Finding What You're Looking For?

Fill out the form below to let us know.